Clearside Biomedical, Inc.

NasdaqGM:CLSD Stock Report

Market Cap: US$66.2m

Clearside Biomedical Past Earnings Performance

Past criteria checks 0/6

Clearside Biomedical's earnings have been declining at an average annual rate of -7.6%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 5.5% per year.

Key information

-7.6%

Earnings growth rate

8.9%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate5.5%
Return on equityn/a
Net Margin-413.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Nov 06
Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Jun 24
We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Nov 12
Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

Aug 11
Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

Clearside Biomedical Q2 2022 Earnings Preview

Aug 08

Clearside Biomedical: A Pivotal 2022 Ahead

Apr 13

Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play

Dec 22

Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business

Sep 30
Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business

Clearside's Value Proposition Is Far From Clear

Aug 07

We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth

Jun 17
We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth

Clearside Biomedical climbs after positive results from early-stage wet AMD trial

Jun 15

Clearside Biomedical resubmits eye treatment XIPERE NDA

May 03

If You Had Bought Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago You'd Have Earned 45% Returns

Feb 16
If You Had Bought Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago You'd Have Earned 45% Returns

Revenue & Expenses Breakdown

How Clearside Biomedical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:CLSD Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 248-321221
30 Jun 248-331122
31 Mar 248-351222
31 Dec 238-321221
30 Sep 232-371220
30 Jun 232-361219
31 Mar 231-351120
31 Dec 221-331220
30 Sep 2227-51218
30 Jun 2229-21219
31 Mar 223001218
31 Dec 213001219
30 Sep 214-251119
30 Jun 214-231118
31 Mar 214-231117
31 Dec 208-181115
30 Sep 2010-141212
30 Jun 207-18139
31 Mar 206-18169
31 Dec 192-311716
30 Sep 190-491732
30 Jun 190-671752
31 Mar 190-821666
31 Dec 180-831568
30 Sep 180-781365
30 Jun 180-721161
31 Mar 180-651055
31 Dec 170-591049
30 Sep 170-521042
30 Jun 170-39930
31 Mar 170-31822
31 Dec 161-26619
30 Sep 161-21516
30 Jun 161-19515
31 Mar 161-19713
31 Dec 150-18711
30 Sep 150-1569
30 Jun 150-1569
31 Mar 150-1248
31 Dec 140-1037
30 Sep 140-936
30 Jun 140-835
31 Mar 140-825

Quality Earnings: CLSD is currently unprofitable.

Growing Profit Margin: CLSD is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CLSD is unprofitable, and losses have increased over the past 5 years at a rate of 7.6% per year.

Accelerating Growth: Unable to compare CLSD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CLSD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).


Return on Equity

High ROE: CLSD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 13:28
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Clearside Biomedical, Inc. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Daniil GataulinChardan Capital Markets, LLC
Yi ChenH.C. Wainwright & Co.
Esther Lannie HongJanney Montgomery Scott LLC